Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

Proteome Analysis

Below the proteome analysis is presented. The analysis methods are presented in the paper Propagating Differential Gene Expression in Protein Interaction Networks. If you are interested in the most reliable results choose the

  • value_type as 'ranked' since this provides a very robust analysis method.
  • intercation map as 'high confidence'
  • network_comparison type as 'Divided' since this leads to a natural grouping of similar proteins
  • filtered as 'true' since this will only use the microarray measurements that have a sufficiently large confidence level.

    • Navigation/Query Panel:
    Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
    Rank Gene Hugo description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
    Results: HTML CSV LaTeX Showing element 908 to 957 of 3228 in total 
    Value Type: Ranked
    Network Comparison Type: Divided
    Interaction Map: High confidence
    Filtered: 1
    
\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
908\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tax interaction protein 1. [source:refseq;acc:nm\_014604]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
223.906\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
215.653\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03827\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
909\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SEPT1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
septin 1 (larp) (serologically defined breast cancer antigen ny-br- 24). [source:swissprot;acc:q8wyj6]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
142.077\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
136.846\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03823\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
910\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
uba/ubx 33.3 kda protein. [source:swissprot;acc:q04323]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
217.168\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
209.207\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03805\vspace{3pt}}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
911\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
ero1-like. [source:refseq;acc:nm\_014584]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
912\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WDR3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
wd-repeat protein 3. [source:swissprot;acc:q9unx4]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
243.896\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
234.96\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03803\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
913\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TGS1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
prip-interacting protein pipmt; prip-interacting protein with methyltransferase domain. [source:refseq;acc:nm\_024831]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
210.863\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
218.878\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03801\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
914\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GOPC\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pdz/coiled-coil domain binding partner for the rho-family gtpase tc10; fused in glioblastoma; golgi associated pdz and coiled-coil motif containing protein; cftr-associated ligand. [source:refseq;acc:nm\_020399]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
915\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRMU\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
trna (5-methylaminomethyl-2-thiouridylate)-methyltransferase (ec 2.1.1.61). [source:swissprot;acc:o75648]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
146.036\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
140.692\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03798\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
916\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HAO2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
hydroxyacid oxidase 2 (ec 1.1.3.15) (haox2) ((s)-2-hydroxy-acid oxidase, peroxisomal) (long chain alpha-hydroxy acid oxidase) (long- chain l-2-hydroxy acid oxidase). [source:swissprot;acc:q9nyq3]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
232.512\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
241.288\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03774\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
917\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CDC73\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
parafibromin. [source:refseq;acc:nm\_024529]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
239.704\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
230.991\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03772\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
918\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SORBS1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ponsin; sh3-domain protein 5 (ponsin). [source:refseq;acc:nm\_015385]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.952\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.292\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03731\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
919\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MDN1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
midasin (midas-containing protein). [source:swissprot;acc:q9nu22]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
237.218\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
228.698\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03725\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
920\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DEAF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
deformed epidermal autoregulatory factor 1 homolog (nuclear deaf-1 related transcriptional regulator) (nudr) (suppressin) (zinc finger mynd domain containing protein 5). [source:swissprot;acc:o75398]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
236.741\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
245.547\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.0372\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
921\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RIOK1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
rio kinase 1 isoform 1; ad034 protein. [source:refseq;acc:nm\_031480]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
922\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MARK1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
map/microtubule affinity-regulating kinase 1. [source:refseq;acc:nm\_018650]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
923\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MARK2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
map/microtubule affinity-regulating kinase 2 isoform b; elkl motif kinase 1; elkl motif kinase. [source:refseq;acc:nm\_004954]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
924\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SPO11\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
meiotic recombination protein spo11. [source:swissprot;acc:q9y5k1]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
925\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PEF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pef protein with a long n-terminal hydrophobic domain (peflin). [source:refseq;acc:nm\_012392]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.665\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.942\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03714\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
926\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
IMMP2L\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
imp2 inner mitochondrial membrane protease-like; inner mitochondrial membrane peptidase 2 like. [source:refseq;acc:nm\_032549]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
217.942\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
210.139\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03713\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
927\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
microsomal signal peptidase 18 kda subunit (ec 3.4.-.-) (spase 18 kda subunit) (spc18) (endopeptidase sp18). [source:swissprot;acc:p21378]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
928\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MTRF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
peptide chain release factor 1, mitochondrial precursor (mrf-1). [source:swissprot;acc:o75570]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
225.976\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
218.017\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03651\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
929\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MPDU1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mannose-p-dolichol utilization defect 1 protein (suppressor of lec15 and lec35 glycosylation mutation homolog) (sl15). [source:swissprot;acc:o75352]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
225.955\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
218.015\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03642\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
930\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PKM2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
pyruvate kinase, m1 isozyme (ec 2.7.1.40) (pyruvate kinase muscle isozyme) (cytosolic thyroid hormone-binding protein) (cthbp) (thbp1). [source:swissprot;acc:p14618]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
231.357\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
239.778\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0364\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
931\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BHLHB4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ba305p22.3 (breast carcinoma amplified sequence 4). [source:sptrembl;acc:q8ndy6]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
159.13\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
164.917\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03637\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
932\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MTRF1L\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mitochondrial translational release factor 1-like. [source:refseq;acc:nm\_019041]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
225.939\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
218.013\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03636\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
933\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BHLHB5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
basic helix-loop-helix domain containing, class b, 5; trinucleotide repeat containing 20. [source:refseq;acc:nm\_152414]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
159.165\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
164.951\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03635\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
934\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NOL6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nucleolar rna-associated protein alpha isoform. [source:refseq;acc:nm\_022917]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
242.024\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
233.544\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03631\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
935\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
sirtuin 7; sir2-related protein type 7; sirtuin type 7; sirtuin (silent mating type information regulation 2, s.cerevisiae, homolog) 7; silent mating type information regulation 2, s.cerevisiae, homolog 7; sirtuin silent mating type information regulation 2 homolog 7 (s. cerevisiae). [source:refseq;acc:nm\_016538]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
232.473\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
224.372\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03611\vspace{3pt}}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
936\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
casein kinase ii beta chain (ck ii) (phosvitin) (g5a). [source:swissprot;acc:p13862]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
937\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SF3A3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
splicing factor 3a subunit 3 (spliceosome associated protein 61) (sap 61) (sf3a60). [source:swissprot;acc:q12874]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
220.246\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
212.618\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03588\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
938\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SF3A1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
splicing factor 3 subunit 1 (spliceosome associated protein 114) (sap 114) (sf3a120). [source:swissprot;acc:q15459]\vspace{3pt}}&&&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
939\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BRCA1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
breast cancer type 1 susceptibility protein. [source:swissprot;acc:p38398]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.501\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
224.27\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
940\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CAPNS1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
calcium-dependent protease, small subunit (calpain regulatory subunit) (calcium-activated neutral proteinase) (canp). [source:swissprot;acc:p04632]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.442\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.088\vspace{3pt}}&\multirow{6}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03586\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
941\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARID1A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
swi/snf-related, matrix-associated, actin-dependent regulator of chromatin subfamily f member 1 (swi-snf complex protein p270) (b120). [source:swissprot;acc:o14497]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.437\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.083\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
942\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GCA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
grancalcin. [source:swissprot;acc:p28676]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
212.442\vspace{3pt}}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.088\vspace{3pt}}&\\\cline{1-3}\cline{5-5}
\parbox{\wcA}{\vspace{3pt}\noindent
943\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SRI\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
sorcin (22 kda protein) (cp-22) (v19). [source:swissprot;acc:p30626]\vspace{3pt}}&&\parbox{\wcE}{\vspace{3pt}\noindent
205.087\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
944\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PDCD6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
programmed cell death protein 6 (probable calcium-binding protein alg- 2). [source:swissprot;acc:o75340]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.437\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.083\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
945\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARID1B\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
brg1-binding protein eld/osa1; eld (eyelid)/osa protein. [source:refseq;acc:nm\_020732]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.44\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.085\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
946\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
histone h4. [source:swissprot;acc:p02304]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
227.765\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
219.902\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03576\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
947\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SORBS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
arg/abl-interacting protein 2 isoform 2; arg binding protein 2. [source:refseq;acc:nm\_021069]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.51\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.191\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03567\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
948\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TOM1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
target of myb protein 1. [source:swissprot;acc:o60784]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.254\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.824\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03541\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
949\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
huntingtin-associated protein-interacting protein (duo protein). [source:swissprot;acc:o60229]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.253\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.826\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0354\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
950\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ERCC5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dna-repair protein complementing xp-g cells (xeroderma pigmentosum group g complementing protein) (dna excision repair protein ercc-5). [source:swissprot;acc:p28715]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
252.873\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
261.821\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03539\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
951\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRIO\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
triple functional domain protein (ptprf interacting protein). [source:swissprot;acc:o75962]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.253\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.827\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
952\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TOM1L2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
target of myb1-like 2; target of myb1 (chicken) homolog-like 2. [source:refseq;acc:nm\_144678]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.252\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.83\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03537\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
953\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EXOSC10\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
polymyositis/scleroderma autoantigen 2 (autoantigen pm/scl 2) (polymyositis/scleroderma autoantigen 100 kda) (pm/scl-100) (p100 polymyositis-scleroderma overlap syndrome associated autoantigen). [source:swissprot;acc:q01780]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
198.494\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
205.466\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03512\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
954\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GSTZ1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
maleylacetoacetate isomerase (ec 5.2.1.2) (maai) (glutathione s- transferase zeta 1) (ec 2.5.1.18) (gstz1-1). [source:swissprot;acc:o43708]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
267.447\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
276.773\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03487\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
955\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MRPL27\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mitochondrial 60s ribosomal protein l27 (l27mt) (hspc250). [source:swissprot;acc:q9p0m9]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
231.163\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
239.205\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03479\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
956\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SORBS3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vinexin (sh3-containing adaptor molecule-1) (scam-1). [source:swissprot;acc:o60504]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
211.812\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
204.732\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03458\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
957\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARAF\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
a-raf proto-oncogene serine/threonine-protein kinase (ec 2.7.1.-) (a-raf-1) (proto-oncogene pks). [source:swissprot;acc:p10398]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
129.913\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
134.399\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03453\vspace{3pt}}\\\hline
nd{longtable}

    Legend:
    - Rank is the rank after comparing the two networks
    
 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray
    
 - Hugo is the HGNC identifier if it exists
    
 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.
    
 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them
    
 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.
    
 - Filtered specifies whether we only included the high confidence microarry measurements or not.
    - http://analysis.yellowcouch.org/